Last year, Traws Pharma Inc generated 2.79M USD for its biggest-performing segment, Symbio. The United States made the largest contribution, accounting for 2.79M USD last year. For the latest quarter, Traws Pharma Inc reported the revenue of 0.00 USD for the period ending 2025-12-31, which came from the top-performing segment, Symbio. United States contributed the highest revenue, at 0.00 USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Symbio

HanX - rigosertib

Knight

STA

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Symbio

2.79M(100.00%)

226.00K(100.00%)

231.00K(100.00%)

282.00K(12.92%)

HanX - rigosertib

--(--)

1.75M(80.21%)

Knight

--(--)

100.00K(4.58%)

STA

--(--)

50.00K(2.29%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

FY2025

United States

2.79M(100.00%)